Apolipoprotein B antibody
ApoB exists in the plasma in 2 main isoforms, ApoB100 and ApoB48. ApoB100 is synthesised in the liver, and is the major apolipoprotein of very low density, intermediate density and low density lipoproteins (LDL), and is absolutely required for their formation.ApoB100 acts as a ligand for LDL receptors in various cells throughout the body, allowing cells to internalise LDL and absorb cholesterol.
ApoB48 is expressed in the intestine and is present on chylomicrons and their remnants, and lacks the C-terminal LDL-receptor binding region of ApoB100. Elevated plasma concentrations of ApoB containing lipoproteins are key risk factors for the development of atherosclerosis.
- Target Species
- Product Form
- Purified IgG - liquid
- Antiserum Preparation
- Antisera to Apolipoprotein B were raised by repeated immunisations of goats with highly purified antigen. Purified IgG prepared by affinity chromatography.
- Buffer Solution
- Borate buffered saline
- Preservative Stabilisers
0.01% Sodium Azide (NaN3)
- Apolipoprotein type B, isolated from human plasma by density gradient centrifugation followed by HPLC purification.
- Approx. Protein Concentrations
- IgG concentration 1.0mg/ml
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 18 months from date of despatch.
Applications of Apolipoprotein B antibody
|Application Name||Verified||Min Dilution||Max Dilution|
- Western Blotting
- AHP1267 detects a band of approximately 550kDa.
Secondary Antibodies Available
|Description||Product Code||Applications||Pack Size||List Price||Quantity|
|Rabbit anti Goat IgG (Fc):FITC||STAR122F||F||1 mg|
|Rabbit anti Goat IgG (Fc):HRP||STAR122P||C E WB||1 mg|
Product Specific References
Olofsson, S.O. & Borèn, J. (2005) Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis.
J Intern Med. 258 (5): 395-410.
Walldius, G. & Jungner, I. (2004) Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy.
J Intern Med. 255 (2): 188-205.